ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0692

Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

Johannes Nowatzky1, Ziyan Lin2, Yesim Ozguler3, Alireza Khodadadi-Jamayran2, Didar Ucar4, Aristotelis Tsirigos5, Gulen Hatemi6 and Olivier Manches7, 1NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, 2NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, 3NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 5NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Behçet's Syndrome, immunology, T Cell, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking, and candidate antigens are elusive. Here, we hypothesized that clonal CD8 T cell expansions are present in BD at tissue sites during active disease aiming to provide evidence of HLA class I restriction by identifying their disease-related CD8 TCR.

Methods: We performed scRNAseq with TCR V(D)J analyses in PBMC from a Turkish cohort of 37 untreated subjects (14 HD, 23 BD) with ocular and vascular BD. In a separate set of experiments, we obtained anterior chamber fluid cells from two additional HLA-B*51+ Behçet’s uveitis (BU) subjects from an independent cohort, as well as time-matched autologous peripheral blood, assessed TCR sequences, clonotype- and T cell phenotype distribution between peripheral blood and the eye, and clonotype sharing across study subjects in both cohorts.

Results: Anterior chamber fluid cells in BU showed substantial oligoclonal CD8 T cell expansions. Highly expanded ocular clonotypes overlapped with autologous peripheral blood exhibiting an intraclonotype shift towards a more cytotoxic (Granzyme B+) phenotype in the eye over peripheral blood. An identical disease-related CD8 a/bTCR, determined in the eye-blood paired sample experiments, was re-identified in HLA-B*51+ active uveitis peripheral blood in the Turkish cohort but not in HDs or BD subjects without uveitis. We identified additional clonotypes which showed high CDR3 sequence similarity to our experimentally determined TCR computationally, using TCRdist. Again, we re-located those in HLA-B*51+ subjects with active uveitis but not in HD, BD without uveitis, or HLA-B*51– subjects.

Conclusion: We demonstrate the presence of highly expanded CD8 T cells in BU eyes and autologous peripheral blood and identify disease-associated TCR across independent cohorts of affected HLA-B*51-carrying subjects but not HDs. Our findings suggest that an HLA class I-restricted process drives BD in a subset of clinically distinct patients and will facilitate antigen discovery by enabling the identification of cognate peptides in an HLA-B*51 restriction context.


Disclosures: J. Nowatzky: None; Z. Lin: None; Y. Ozguler: None; A. Khodadadi-Jamayran: None; D. Ucar: None; A. Tsirigos: None; G. Hatemi: None; O. Manches: None.

To cite this abstract in AMA style:

Nowatzky J, Lin Z, Ozguler Y, Khodadadi-Jamayran A, Ucar D, Tsirigos A, Hatemi G, Manches O. Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/behcets-disease-associated-tcr-in-the-eye-points-to-hla-class-i-restricted-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-associated-tcr-in-the-eye-points-to-hla-class-i-restricted-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology